Localized vs. Systemic Scleroderma: Key Differences in Presentation and Management
Localized Scleroderma (Morphea)
- Affects skin only (dermis/subcutis)
- Plaques: hard, thickened, hyper-/hypopigmented
- May itch or hurt
- Peak onset: children & young adults
- Treatment: topical corticosteroids, calcipotriene, phototherapy (UVA1)
- Prognosis: often self-limited; remission in 3–5 years
Systemic Scleroderma (Systemic Sclerosis, PSS)
- Affects skin + internal organs + vasculature
- Skin tightening + Raynaud’s, digital ulcers, ILD, PAH, renal crisis, GI dysmotility
- Peak onset: women 30–50
- Treatment: immunosuppressants (methotrexate, mycophenolate), vasodilators, antifibrotics, organ-specific therapy
- Prognosis: variable; 10-year survival ~70–80% with modern care
Early rheumatology referral is crucial for systemic disease to screen for organ involvement and initiate disease-modifying therapy.
Multiple Sclerosis - Related Articles
- Understanding Multiple Sclerosis (MS) Treatments: A Comprehensive Overview
- The Best Resources for MS Treatment Advice
- Multiple Sclerosis and Action Potentials: How Demyelination Disrupts Nerve Signaling
- Neck Pain & MS: Understanding Symptoms & Potential Connections
- Doctor Discussion: Is Your MS Treatment Plan Working?
- J.K. Rowling and Health: Exploring Reports and Diagnoses
- Subacute Sclerosing Panencephalitis (SSPE): Onset Timeline After Measles
